A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer

William M. Lydiatt, David Denman, Dennis P. McNeilly, Susan E. Puumula, William J. Burke

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To determine whether prophylactic treatment with the antidepressant citalopram hydrobromide, compared with placebo, could prevent major depressive disorder in patients undergoing therapy for head and neck cancer (HNC). Design: Prospective, randomized, placebo-controlled trial. Setting: Academic medical center. Patients: Thirty-six subjects were randomized, and 23 completed the study. Interventions: Subjects were randomized to receive 40 mg of citalopram hydrobromide or matching placebo (hereinafter, citalopram group and placebo group, respectively) for 12 weeks with a final visit at 16 weeks. Main Outcome Measures: The Hamilton Depression Rating Scale, psychiatric interview, and the University of Washington Quality of Life (UW-QOL) and Clinician Global Impression-Severity (CGI-S) scales. Results: The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were 5 of 10 (50%) taking placebo and 2 of 12 (17%) taking citalopram (Fisher exact test, P = .17). No patients in the citalopram group became suicidal, compared with 2 in the placebo group. Global mood state at the conclusion of the study as measured by the CGI-S scale was rated as at least mildly ill in 15% of those receiving citalopram compared with 60% in the placebo group (Fisher exact test, P = .04). Quality of life, measured by the UW-QOL, deteriorated in both groups from baseline but less so in the citalopram group. Conclusions: This study reports data from the first depression prevention trial in HNC and suggests that prophylactic treatment may decrease the incidence of depression during HNC therapy. The clinical significance of the reduction in depression was best demonstrated by the CGI-S scale, which showed a notable difference in global psychiatric and physical well-being.

Original languageEnglish (US)
Pages (from-to)528-532
Number of pages5
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume134
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Citalopram
Head and Neck Neoplasms
Randomized Controlled Trials
Placebos
Depression
Quality of Life
Therapeutics
Psychiatry
Major Depressive Disorder
Antidepressive Agents
Outcome Assessment (Health Care)
Interviews
Incidence

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. / Lydiatt, William M.; Denman, David; McNeilly, Dennis P.; Puumula, Susan E.; Burke, William J.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 134, No. 5, 01.05.2008, p. 528-532.

Research output: Contribution to journalArticle

Lydiatt, William M. ; Denman, David ; McNeilly, Dennis P. ; Puumula, Susan E. ; Burke, William J. / A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. In: Archives of Otolaryngology - Head and Neck Surgery. 2008 ; Vol. 134, No. 5. pp. 528-532.
@article{01f4d5603ac142bab435f518624a1e9d,
title = "A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer",
abstract = "Objective: To determine whether prophylactic treatment with the antidepressant citalopram hydrobromide, compared with placebo, could prevent major depressive disorder in patients undergoing therapy for head and neck cancer (HNC). Design: Prospective, randomized, placebo-controlled trial. Setting: Academic medical center. Patients: Thirty-six subjects were randomized, and 23 completed the study. Interventions: Subjects were randomized to receive 40 mg of citalopram hydrobromide or matching placebo (hereinafter, citalopram group and placebo group, respectively) for 12 weeks with a final visit at 16 weeks. Main Outcome Measures: The Hamilton Depression Rating Scale, psychiatric interview, and the University of Washington Quality of Life (UW-QOL) and Clinician Global Impression-Severity (CGI-S) scales. Results: The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were 5 of 10 (50{\%}) taking placebo and 2 of 12 (17{\%}) taking citalopram (Fisher exact test, P = .17). No patients in the citalopram group became suicidal, compared with 2 in the placebo group. Global mood state at the conclusion of the study as measured by the CGI-S scale was rated as at least mildly ill in 15{\%} of those receiving citalopram compared with 60{\%} in the placebo group (Fisher exact test, P = .04). Quality of life, measured by the UW-QOL, deteriorated in both groups from baseline but less so in the citalopram group. Conclusions: This study reports data from the first depression prevention trial in HNC and suggests that prophylactic treatment may decrease the incidence of depression during HNC therapy. The clinical significance of the reduction in depression was best demonstrated by the CGI-S scale, which showed a notable difference in global psychiatric and physical well-being.",
author = "Lydiatt, {William M.} and David Denman and McNeilly, {Dennis P.} and Puumula, {Susan E.} and Burke, {William J.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1001/archotol.134.5.528",
language = "English (US)",
volume = "134",
pages = "528--532",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - A randomized, placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer

AU - Lydiatt, William M.

AU - Denman, David

AU - McNeilly, Dennis P.

AU - Puumula, Susan E.

AU - Burke, William J.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Objective: To determine whether prophylactic treatment with the antidepressant citalopram hydrobromide, compared with placebo, could prevent major depressive disorder in patients undergoing therapy for head and neck cancer (HNC). Design: Prospective, randomized, placebo-controlled trial. Setting: Academic medical center. Patients: Thirty-six subjects were randomized, and 23 completed the study. Interventions: Subjects were randomized to receive 40 mg of citalopram hydrobromide or matching placebo (hereinafter, citalopram group and placebo group, respectively) for 12 weeks with a final visit at 16 weeks. Main Outcome Measures: The Hamilton Depression Rating Scale, psychiatric interview, and the University of Washington Quality of Life (UW-QOL) and Clinician Global Impression-Severity (CGI-S) scales. Results: The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were 5 of 10 (50%) taking placebo and 2 of 12 (17%) taking citalopram (Fisher exact test, P = .17). No patients in the citalopram group became suicidal, compared with 2 in the placebo group. Global mood state at the conclusion of the study as measured by the CGI-S scale was rated as at least mildly ill in 15% of those receiving citalopram compared with 60% in the placebo group (Fisher exact test, P = .04). Quality of life, measured by the UW-QOL, deteriorated in both groups from baseline but less so in the citalopram group. Conclusions: This study reports data from the first depression prevention trial in HNC and suggests that prophylactic treatment may decrease the incidence of depression during HNC therapy. The clinical significance of the reduction in depression was best demonstrated by the CGI-S scale, which showed a notable difference in global psychiatric and physical well-being.

AB - Objective: To determine whether prophylactic treatment with the antidepressant citalopram hydrobromide, compared with placebo, could prevent major depressive disorder in patients undergoing therapy for head and neck cancer (HNC). Design: Prospective, randomized, placebo-controlled trial. Setting: Academic medical center. Patients: Thirty-six subjects were randomized, and 23 completed the study. Interventions: Subjects were randomized to receive 40 mg of citalopram hydrobromide or matching placebo (hereinafter, citalopram group and placebo group, respectively) for 12 weeks with a final visit at 16 weeks. Main Outcome Measures: The Hamilton Depression Rating Scale, psychiatric interview, and the University of Washington Quality of Life (UW-QOL) and Clinician Global Impression-Severity (CGI-S) scales. Results: The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were 5 of 10 (50%) taking placebo and 2 of 12 (17%) taking citalopram (Fisher exact test, P = .17). No patients in the citalopram group became suicidal, compared with 2 in the placebo group. Global mood state at the conclusion of the study as measured by the CGI-S scale was rated as at least mildly ill in 15% of those receiving citalopram compared with 60% in the placebo group (Fisher exact test, P = .04). Quality of life, measured by the UW-QOL, deteriorated in both groups from baseline but less so in the citalopram group. Conclusions: This study reports data from the first depression prevention trial in HNC and suggests that prophylactic treatment may decrease the incidence of depression during HNC therapy. The clinical significance of the reduction in depression was best demonstrated by the CGI-S scale, which showed a notable difference in global psychiatric and physical well-being.

UR - http://www.scopus.com/inward/record.url?scp=44249104205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249104205&partnerID=8YFLogxK

U2 - 10.1001/archotol.134.5.528

DO - 10.1001/archotol.134.5.528

M3 - Article

VL - 134

SP - 528

EP - 532

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 5

ER -